$3.32
0.165.06%
Last update: Nov 6, 4:22 PM
Indaptus Therapeutics Inc (INDP) Stock Price, Quote, News & History
INDPNASDAQ
Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.
You can purchase shares of Indaptus Therapeutics (NASDAQ:INDP) through any online brokerage.
Other companies in Indaptus Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Indaptus Therapeutics has a consensus price target of $238.00.
The stock price for Indaptus Therapeutics (NASDAQ: INDP) is $3.25 last updated November 6, 2026 at 4:22 PM EST.
There are no upcoming dividends for Indaptus Therapeutics.
Indaptus Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Indaptus Therapeutics.
Indaptus Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate...
